GOLD ABE Group (COPD) — free guideline decision tool
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Exacerbations in the past year | None (0 moderate/severe exacerbations) |
|---|---|
| Symptom burden | mMRC 0–1 (CAT < 10) |
→GOLD groupGroup A
- Exacerbation risk：Low
- Symptoms：Low (mMRC 0–1 / CAT < 10)
| Exacerbations in the past year | ≥ 1 moderate or ≥ 1 hospitalization (severe) |
|---|---|
| Symptom burden | mMRC ≥ 2 (CAT ≥ 10) |
→GOLD groupGroup E
- Exacerbation risk：High (→ E)
- Symptoms：High (mMRC ≥ 2 / CAT ≥ 10)
Common questions
What is GOLD ABE Group (COPD)?
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
How is GOLD ABE Group (COPD) calculated? What is the core formula?
Group E for ≥ 1 moderate exacerbation or ≥ 1 hospitalization in the past year (initial LABA+LAMA, consider ICS if eosinophils ≥ 300); otherwise group B (mMRC ≥ 2/CAT ≥ 10 → LABA+LAMA) or group A (low symptoms → single bronchodilator).
When is GOLD ABE Group (COPD) used?
Use to assign group A, B, or E and select initial inhaled therapy in stable COPD.
What are the key clinical points for GOLD ABE Group (COPD)?
From the 2023 revision the former C/D groups merged into a single high-risk group E, simplifying the matrix (original synthesis · not guideline verbatim). GOLD 2026 lowered the bar — even one moderate exacerbation places a patient in group E. Airflow-limitation grade (GOLD 1–4 by FEV1%) is reported separately and does not set the letter group.
What are the limits and cautions when using GOLD ABE Group (COPD)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is GOLD ABE Group (COPD) calculated in practice? Can you show a worked example?
Inputs: Exacerbations in the past year None (0 moderate/severe exacerbations), Symptom burden mMRC 0–1 (CAT < 10) → Result: GOLD group Group A（Exacerbation risk: Low, Symptoms: Low (mMRC 0–1 / CAT < 10)） Inputs: Exacerbations in the past year ≥ 1 moderate or ≥ 1 hospitalization (severe), Symptom burden mMRC ≥ 2 (CAT ≥ 10) → Result: GOLD group Group E（Exacerbation risk: High (→ E), Symptoms: High (mMRC ≥ 2 / CAT ≥ 10)）
Run GOLD ABE Group (COPD) now
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.